ANALIZE MEDICALE DE LABORATOR
            Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
            Selectati o categorie din lista de mai jos:
            
         
     
    
    
    
        Solutie antistress!
 Construieste poduri :)
         Prinde pisica neagra :)
        
        Prinde pisica neagra :)
         
     
 
EndoGastric Solutions(TM) Announces Results Of EsophyX(TM) Multi-Center GERD Study
EndoGastric Solutions, the 
  world leader in natural orifice surgery products and 
  procedures, announces outstanding results at the completion 
  of 1-year follow-up on GERD patients in the phase 2 
  multi-center study of the first generation transoral 
  incisionless fundoplication (TIF 1) procedure and 
  first-generation EsophyX device. EndoGastric Solutions is 
  the first company to successfully design truly incisionless 
  transoral surgical products that mimic the outcomes of the 
  more invasive gold-standard antireflux surgeries, 
  laparoscopic fundoplications (i.e. Nissen, Toupet or Hill 
  procedures). The EsophyX device enables surgeons and 
  advanced interventional gastroenterologists to offer their 
  patients substantive anatomical repair without incisions (no 
  skin or internal dissection) for front-line surgical 
  management of gastroesophageal reflux disease (GERD) 
  patients.
  
  Dr. John Hunter, Professor and Chairman of the Department of 
  Surgery at Oregon Health & Science University in Portland, 
  Oregon, states, "For years, the medical community has been 
  looking for less invasive ways to treat GERD patients to 
  reduce their dependence on pharmaceuticals. Our department 
  has studied the effects of these pharmaceuticals and is 
  concerned that there are additional detrimental effects that 
  should be avoided. EsophyX is an impressive technology with 
  impressive results that advances the treatment of GERD a 
  giant leap forward."
  
  Dr. Todd Overcash, Medical Director of Bariatric and 
  Minimally Invasive Surgery at Munroe Regional Medical Center 
  in Ocala, Florida, is the United States leader of NOS 
  (Natural Orifice Surgery) procedures performed. He was among 
  the first U.S. surgical teams that went to Europe last fall 
  to train on this new technique. He has now performed more 
  EsophyX procedures than any surgeon in the U.S. and states: 
  "Having performed 38 advanced TIF procedures with the 
  EsophyX device in the last three months, I can attest that 
  this incisionless technique offers our patients a tremendous 
  improvement in their quality of life. It allows them the 
  ability to eat foods and beverages they could not tolerate 
  before the procedure but, most importantly, it allows them 
  to discontinue their use of GERD medications in the majority 
  of cases, which is especially important for women in the 
  face of osteoporosis. With no skin incisions, no cutting of 
  vessels, and no dissection of the fundus, the EsophyX device 
  represents a new era in antireflux treatment and offers 
  patients an innovative, state-of-the-art surgical procedure 
  that will allow them to no longer live their lives 
  pill-to-pill."
  
  Dr. Scott Melvin, Professor of Surgery, Director of the  
  Center for Minimally Invasive Surgery and Chief of the 
  Division of General & Gastrointestinal Surgery at The Ohio 
  State University (OSU) Medical Center, will be demonstrating 
  this new TIF technique at a live case course at OSU February 
  29th: "I am very impressed with the clinical results for 
  EsophyX, including the reduction/elimination of hiatal 
  hernia and reduction/elimination of esophagitis. These 
  multi-center study results confirm the 2 year outcomes seen 
  in the first EsophyX study. With over 750 Natural Orifice 
  Surgical cases performed to date, utilizing EndoGastric 
  Solutions technology platforms, it is clear that TIF is a 
  mainstream procedure that most advanced foregut surgeons 
  should be incorporating into their clinical practice. Any 
  surgeon considering being a natural orifice surgeon should 
  come see the techniques and learn more at our course."
  
  "We are very pleased with the outstanding results of our 
  first two GERD clinical studies," states Thierry Thaure, CEO 
  of EndoGastric Solutions (EGS) Inc. "These results were 
  achieved with the first version of the EsophyX device and 
  TIF 1 procedure. We believe in continuous improvement and 
  are already teaching a much improved TIF 2 technique in our 
  training center in Redmond, Washington that has shown even  
  stronger outcomes. We are encouraged that surgeons and 
  advanced surgical endoscopists are rapidly adopting these 
  new incisionless procedures, as patients are demanding a 
  permanent solution for their reflux disease in the face of 
  failing pharmacological therapy."
  
  About EndoGastric Solutions
  
  EndoGastric Solutions (EGS) is a privately held corporation 
  located in Redmond, Washington and Redwood City, California. 
  EGS is a pioneer in developing incisionless transoral 
  procedures for the treatment of upper gastrointestinal 
  diseases, including gastroesophageal reflux disease (GERD) 
  and other GI conditions. EsophyX and StomaphyX(TM) are 
  cleared by the FDA for specific indications, are CE marked, 
  and are available for sale in the U.S. and Europe.
  
  For more information about EndoGastric Solutions, Inc., 
  EsophyX(TM) and StomaphyX(TM), please visit:
  
  US: http://www.endogastricsolutions.com
  EU: http://www.egseurope.eu
  Other locations: http://www.egsglobal.net
  
  For more information about the Ohio State University Medical 
  Center Leap into the Future with Advances in Transoral 
  Foregut Surgery course please visit:
  http://www.cmis.ohio-state.edu 
EndoGastric Solutions
		
EndoGastric soluþii (tm) anunta rezultatele EsophyX (tm) multi-Gerd Centrul de studiu - EndoGastric Solutions(TM) Announces Results Of EsophyX(TM) Multi-Center GERD Study - articole medicale engleza - startsanatate